The results showed that treatment by FK@IQ-4T1+L at the distant site moderately inhibited the recurrence of 4T1 primary tumor (Supplementary Fig. 17a–c), suggesting tumor-specific delivery of JQ-1 is critical for tumor recurrence prevention by suppressing PD-L1-mediated immune evasion. Here, CD274 is linked to neoplasm.